Published in final edited form as:

Environ Mol Mutagen. 2020 October ; 61(8): 807–819. doi:10.1002/em.22393.

Human blood *PIG-A* mutation and micronucleated reticulocyte flow cytometric assays: Method optimization and evaluation of intra- and inter-subject variation

Dorothea K. Torous¹, Svetlana L. Avlasevich¹, Mona G. Khattab², Ayesha Baig³, Lawrence J. Saubermann³, Yuhchayau Chen⁴, Jeffrey C. Bemis¹, David P. Lovell⁵, Vernon E. Walker⁶, James T. MacGregor⁷, Stephen D. Dertinger¹

¹Litron Laboratories, Rochester, New York

²Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas

³Department of Pediatrics, University of Rochester Medical Center, Rochester, New York

⁴Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York

⁵St. George's, University of London, London, UK

⁶Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont

⁷Toxicology Consulting Services, Bonita Springs, Florida

Abstract

We previously described flow cytometry-based methods for scoring the incidence of micronucleated reticulocytes (MN-RET) and *PIG-A* mutant phenotype reticulocytes (MUT RET) in rodent and human blood samples. The current report describes important methodological improvements for human blood analyses, including immunomagnetic enrichment of CD71-positive reticulocytes prior to MN-RET scoring, and procedures for storing frozen blood for later *PIG-A* analysis. Technical replicate variability in MN-RET and MUT RET frequencies based on blood specimens from 14 subjects, intra-subject variability based on serial blood draws from 6 subjects, and inter-subject variation based on up to 344 subjects age 0 to 73 years were quantified. Inter-subject variation explained most of the variability observed for both endpoints (77%), with much lower intra-subject and technical replicate variability. The relatively large degree of inter-subject variation is apparent from mean and standard deviation values for MN-RET (0.15

Correspondence: Stephen D. Dertinger, Litron Laboratories, 3500 Winton Place, Rochester, NY 14623. sdertinger@litronlabs.com. AUTHOR CONTRIBUTIONS

Mona G. Khattab, Ayesha Baig, Lawrence J. Saubermann, Yuhchayau Chen, Jeffrey C. Bemis, and Vernon E. Walker gained the approvals necessary to conduct human subject research at their respective institutions. Jeffrey C. Bemis, David P. Lovell, James T. MacGregor, and Stephen D. Dertinger designed the scale and scope of the study. Mona G. Khattab, Ayesha Baig, and Yuhchayau Chen oversaw recruitment of volunteers, and Dorothea K. Torous managed the purchasing and scheduling of commercially-supplied blood samples. Dorothea K. Torous and Svetlana L. Avlasevich performed the blood processing and flow cytometric analyses. Statistical analyses were performed by Stephen D. Dertinger under the guidance of David P. Lovell. Stephen D. Dertinger wrote a draft manuscript, and all authors contributed to the substantial revisions that followed.

CONFLICT OF INTEREST

D.K.T., S.L.A., J.C.B. and S.D.D. are employed by Litron Laboratories. Litron owns patents covering the flow cytometry-based assays described in this manuscript and plans to sell commercial kits based on these procedures: J.T.M. serves as a consultant to Litron.

$\pm 0.10\%$) and MUT RET (4.7 ± 5.0 per million, after omission of two extreme outliers). The influences of age and sex on inter-subject variation were investigated, and neither factor affected MN-RET whereas both influenced MUT RET frequency. The lowest MUT RET values were observed for subjects <11 years old, and males had moderately higher frequencies than females. These results indicate that MN-RET and MUT RET are automation-compatible biomarkers of genotoxicity that bridge species of toxicological interest to include human populations. These data will be useful for appropriately designing future human studies that include these biomarkers of genotoxicity, and highlight the need for additional work aimed at identifying the sources of inter-individual variability reported herein.

Keywords

biomonitoring; chromosomal damage; flow cytometry; genotoxicity; mutation

1 | INTRODUCTION

DNA damage plays integral roles in many human diseases, including cancer, the numerous Mendelian genetic diseases, atherosclerosis, and DNA-repair deficiency diseases (Hoeijmakers, 2009). In addition to the role genomic damage plays in cancer and other diseases, a consortium of experts at the Health and Environmental Sciences Institute have recently advocated that mutation should be considered an adverse outcome in its own right (Heflich *et al.*, 2020). Despite its importance, the systematic study of DNA damage and identification of causative factors are hampered by the lack of rapid, sensitive, and economical in vivo assays that can be readily applied to human specimens. Adaptation of two flow cytometry-based assays that are widely used for rodent studies to human blood samples may overcome these obstacles—micronucleated reticulocyte (MN-RET) and *PIG-A* mutant reticulocyte (MUT RET) analyses (Dertinger *et al.*, 2004, 2011).

The MN-RET assay is responsive to chromosomal damage that results in DNA double-strand breaks or mal-segregation of chromosomes (Heddle, 1973; MacGregor *et al.*, 1980; Hayashi *et al.*, 2000), and the *PIG-A* assay reports the occurrence of inactivating gene mutations (Araten *et al.*, 1999; Gollapudi *et al.*, 2015). Together they represent complementary biomarkers that cover a wide range of genotoxic lesions. We anticipate that an efficient and reliable human blood-based strategy for quantifying chromosomal damage and gene mutation would benefit myriad lines of investigation. These include, but are not limited to: identification of genotoxic environmental or occupational exposures; development of pharmaceuticals, consumer products, and industrial chemicals with inherently lower genotoxicity; identification of unhealthy lifestyle choices; studying the consequences of diagnostic and therapeutic radiation; identifying subjects at high risk for certain diseases; and detection of genotypes associated with increased rates of DNA damage.

This laboratory and others have previously reported significant progress adapting these rodent assays to human blood analyses (Dertinger *et al.*, 2004, 2007, 2015; Grawé *et al.*, 2005; Offer *et al.*, 2005; Witt *et al.*, 2007; Dobrovolsky *et al.*, 2011; Cao *et al.*, 2016, 2020a, 2020b; Horibata *et al.*, 2016; Khattab *et al.*, 2017; Haboubi *et al.*, 2019). Here,

we report methodological improvements that overcome barriers to wide-spread use. One obstacle stems from the fact that the flow cytometric approach to scoring peripheral blood micronuclei is based on the analysis of the most immature fraction of erythrocytes, that is, the CD71-positive fraction of reticulocytes, which are present at a very low frequency of about 0.1% in the human blood circulation. Focusing analyses on these most immature reticulocytes is advantageous because it minimizes the impact of splenic filtration function has on micronucleated erythrocyte frequencies (Dertinger *et al.*, 2004, 2007). However, this low frequency has made it challenging to interrogate adequate numbers of reticulocytes to precisely measure %MN-RET. Informed by work by Grawé *et al.* (2005), we have developed an immunomagnetic method that overcomes this problem by enriching CD71-positive reticulocytes prior to flow cytometric analysis.

Another limitation has been the requirement to label and analyze blood samples for the *PIG-A* assay within several days of collection. Here, we report that methods recently developed for freezing and later thawing rodent blood samples for mutation analysis (Avlasevich *et al.* 2019) are effective with human blood. This is an important advance that overcomes numerous logistical issues that would otherwise interfere with many, if not most, human biomonitoring studies.

Another significant barrier to routinely incorporating MN-RET and MUT RET biomarkers into human population studies has been the scarcity of data from presumably healthy human subjects. In order to design adequately powered studies, it is important to understand the distribution of healthy volunteer data once technical sources of variability have been minimized, and to be cognizant of host factors that have an appreciable influence on MN-RET and MUT RET frequencies. Therefore, after optimizing these assays, we assessed technical replicate variability and intra-subject variability over a 5-week period based on 6 individuals, and inter-subject variation based on 344 individuals. We also investigated the influence of age and sex on MN-RET and MUT RET frequencies. The results of these experiments form the basis of the recommendations we provide for effectively incorporating these biomarkers into human biomonitoring studies.

2 | MATERIALS AND METHODS

2.1 | Mouse study

2.1.1 | Mice—Male CD-1 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). Mice were allowed to acclimate for at least 1 week prior to treatment, and were handled in accordance with the standards established by the U.S. Animal Welfare Acts set forth in the National Institutes of Health (NIH) guidelines. All procedures were reviewed and approved by the University of Rochester's Committee on Animal Resources. Purina Mills Rodent Chow 5001 and water were available ad libitum.

2.1.2 | Mouse blood micronucleus assay: Reagents—Absolute methanol and heat-inactivated fetal bovine serum (FBS; cat. no. 89510-186) were from VWR, Radnor, PA. Reagents used for flow cytometric MN-RET scoring (Anticoagulant Solution, Buffer Solution, DNA Stain, Anti-CD71-FITC and Anti-CD61-PE Antibodies, RNase Solution, and Malaria Biostandards) were from In Vivo MicroFlow® PLUS-M Kits, Litron Laboratories,

Rochester, NY. FITC Selection Cocktail and Magnetic Nanoparticles (cat. no. 18555) were from STEMCELL Technologies Inc., Vancouver, Canada.

2.1.3 | Treatment, blood collection—At the time of treatment mice were approximately 6 weeks old. Ionizing radiation doses were 0.5, 1, 2, and 4 Gy, and sham irradiation was used as the negative control. Three mice were randomly selected for each group, and total body irradiation was performed with a single exposure to ^{137}Cs gamma rays. The dose rate was approximately 2 Gy per minute. After irradiation, the mice were maintained in groups of 3 per cage in a pathogen-free room. Blood samples were collected 24 hr post-exposure via an incision to a tail vein after mice were warmed briefly under a heat lamp. Approximately 50 μl of free-flowing blood was collected into tubes containing 200 μl kit-supplied Anticoagulant Solution which was maintained at room temperature until fixation occurred (within 4 hr). Blood samples were fixed with ultracold methanol according to Mouse MicroFlow^{PLUS} Kit instructions. These fixed blood specimens were returned to the ultracold freezer for storage until flow cytometric analyses were performed as described below.

2.1.4 | Mouse blood micronucleus assay: Sample processing and flow cytometric analysis—Fixed blood samples were washed out of methanol, cells were pelleted via centrifugation, and supernatants were aspirated according to manufacturer recommendations (In Vivo MicroFlow[®] PLUS-M Kit instruction manual, www.litronlabs.com). Tubes were gently tapped to resuspend the cells and 100 μl of Buffer Solution were added. The entire volume of each tube was transferred into a new 96-well round bottom assay plate (Falcon cat. no. 353910) with pre-aliquoted 100 μl working Labeling Solution (anti-CD71-FITC, anti-CD61-PE and RNase). Samples were incubated for 30 min at 4°C and then 30 min at room temperature, at which point cells were resuspended by gentle pipetting and transferred directly into 1.5 ml ice-cold Buffer +1% FBS that was pre-aliquoted into wells of a 96-well deep-well plate (Axygen Scientific cat. no. P-DW-20-C). Cells were collected via centrifugation at 340g for 5 min. After centrifugation and aspiration of supernatant, cells were resuspended in 75 μl ice-cold Buffer Solution and kept cold and protected from light. A small aliquot (10 μl) of each cell suspension was transferred to a 96-well round bottom plate containing 50 μl of ice-cold Buffer and was used for standard MicroFlow sample analysis and stored at 4°C until flow cytometric analysis occurred as described below (same day).

The remainder (majority) of each sample was used for reticulocyte enrichment. The entire volume of labeled cells was moved to a new well of a 96-well round bottom assay plate (Falcon cat. no. 353910) containing 50 μl of FITC selection cocktail (5 μl per 100 μl of Buffer), mixed gently by pipetting, and incubated at room temperature for 15 min. Cells were then moved to a new set of wells containing 50 μl of magnetic nanoparticles, mixed well and incubated for 10 min at room temperature. Cell suspensions (150 μl) were transferred to a new set of wells on a standard 96-well round bottom plate and a 96-well format Magnetic Bead Extractor (V&P Scientific's Magnetic Bead Separation Extractor, cat. no. 407AM-N) that was sheathed with a PCR cover plate (V&P Scientific's PCR plate, cat. no. VP 407AM-N-PCR). The magnetic beads with attached CD71-FITC cells were extracted

from the cell mixture after 10 min incubation at room temperature. The magnet and cover were then moved into wells of a sister plate containing 150 μ l per well pre-aliquoted DNA Staining Solution. At this point, the cover plate was detached from the magnetic pins and the beads were released into the DNA Staining Solution. The plate was stored at 4°C and protected from light until flow cytometric analysis occurred as described below (same day).

Samples were analyzed by a flow cytometer equipped with a 488-nm laser (FACSCanto™ II running FACSDiva™ v6.1.3, Becton Dickinson, San Jose, CA). Anti-CD71-FITC, anti-CD61-PE, and propidium iodide fluorescence signals were detected in the FITC, PE, and PerCP-Cy5.5 channels, respectively. The gating logic used to ensure that quantitative analyses of erythrocyte subpopulations were not contaminated by other cellular or noncellular events has been described previously (Dertinger *et al.*, 2004). Calibration of the flow cytometer was accomplished by staining malaria-infected erythrocytes in parallel with test samples on each day of analysis (Tometsko *et al.*, 1994). The stop mode was set so that 20,000 CD71 + RETs per blood sample were evaluated for micronuclei, and the percentage of MN-RET and RET were calculated with Microsoft® Excel for Mac (v16.16.14).

2.1.5 | Statistical analyses—Each mouse blood sample was split between two methods to generate %MN-RET values—standard MicroFlow analysis, and MicroFlow analysis following immunomagnetic enrichment of CD71+ RET. A linear fit was calculated in Excel. The resulting slope factor (m) was used to characterize accuracy, while the correlation coefficient (r^2) was calculated to describe precision. As described in the fundamental works of Altman and Bland (1983), a correlation analysis does not describe measurement performance sufficiently. Therefore, the methodology proposed by Bland and Altman was also applied, also using Excel. In doing so, differences versus averages of %MN-RET values with and without immunomagnetic separation were plotted to describe bias and dispersion structures. Upper and lower limits of agreement were calculated to provide additional quantitative information about method performance.

2.2 | Human subject studies

2.2.1 | Subject information—Three hundred sixty-three subjects, all under IRB-approved protocols, provided informed consent and donated blood sample(s) via venipuncture of the median cubital or cephalic vein at the cubital fossa. Blood was collected into a single 4 or 10 ml K₂-EDTA vacutainer tube. The sources of the blood samples and subject characteristics are described in Table 1. Thirty-seven volunteers provided blood samples at the University of Rochester Medical Center or an affiliated clinic, in which case the local samples were transported to Litron in Exakt Paks with –20°C ice packs to keep them cold but not frozen during same day delivery. The majority of the samples (300) were purchased from Biological Specialty Company (Colmar, PA). These samples, as well blood collected at Texas Children's Hospital, required overnight transportation. In these cases, K₂-EDTA vials were shipped in Exakt Pak or comparable containers with –20°C ice packs in order to keep them cold, not frozen during FedEx First Overnight delivery service.

2.2.2 | Human blood micronucleus assay: Reagents—Absolute methanol and heat-inactivated fetal bovine serum (FBS; cat. no. 89510-186) were from VWR, Radnor,

PA. Reagents used for flow cytometric MN-RET scoring (Anticoagulant Solution, Buffer Solution, DNA Stain, Anti-CD71-FITC and Anti-CD61-PE Antibodies, RNase Solution, and Malaria Biostandards) were from Prototype in vivo MicroFlow® PLUS-H Kits, Litron Laboratories, Rochester, NY. Anti-FITC MicroBeads, MS Columns, and an OctoMACS™ Separator were from Miltenyi Biotec, Bergisch Gladbach, Germany.

2.2.3 | Human blood micronucleus assay: Sample processing and flow cytometric analysis—The methods for preparing human blood samples for MN-RET scoring are similar to those described previously (Dertinger *et al.*, 2004, 2007). However, after incubating fixed blood samples with RNase, anti-CD71-FITC, and anti-CD61-PE, the cells were exposed to an anti-FITC microbead solution. That is, superparamagnetic anti-FITC MicroBeads in Buffer Solution +1% FBS (5 µl/100 ml) were added to each sample in a volume of 100 µl and were mixed with gentle pipetting. Following a 30 min incubation at 4°C, 1 ml cold Buffer Solution +1% FBS was added to each sample and cells were mixed with gently pipetting. Each sample was divided into two fractions: “pre-column” and “post-column”. For pre-column samples, a 20 µl aliquot of each cell suspension was added to 280 µl working DNA Stain and samples were placed on ice or at 4°C until flow cytometric analysis occurred as described below (same day). The remainder (majority) of each sample was applied to a pre-wetted Miltenyi MS Column suspended in an OctoMACS Separator. Once all of the unlabeled cells passed through the column, each MS column was washed three times with 500 µl Buffer Solution +1% FBS. At this point each MS column was removed from the magnetic field and placed onto a 15 ml centrifuge tube. Two milliliters Buffer Solution +1% FBS was added to each column reservoir to gently flush out the bound reticulocytes using the plunger supplied with the columns. After centrifugation (5 min at 800g) and aspiration, cell pellets were tapped loose, and stored on wet ice until flow cytometric analysis occurred as described below (same day).

At the beginning of each FCM analysis day, instrumentation and acquisition/analysis software parameters were calibrated based on the fluorescence of a biological standard— kit supplied malaria-infected rat blood (methanol fixed). As described previously, this sample guided photomultiplier tube voltages and compensation settings to resolve parasitized reticulocytes and also guided the position of the micronucleus scoring region. Data acquisition and analyses were performed using a FACSCalibur flow cytometer providing 488 nm excitation, running CellQuest™ Pro software v5.2.

Once photomultiplier tube voltages and compensation settings were configured with the malaria biostandard, the pre- and post-column paired samples were analyzed. Pre-column sample data acquisition occurred until 300,000 total erythrocytes were collected. While the pre-column sample was being analyzed, 300 µl of the same working DNA stain was added to each post-column tube and the entire volume was transferred into a standard flow cytometer tube. Each sample was analyzed so that at least 10,000, but preferably 20,000 CD71-positive RET were analyzed. Note that we do not report %MN-RET for 18 of 356 samples (5% of total) because pre-column RET was <0.02% and we were unable to acquire at least 10,000 RET.

2.2.4 | Human blood *PIG-A* assay: Reagents—Lympholyte[®]-H was purchased from CedarLane, Burlington, NC. Anti-PE MicroBeads, LS Columns, and QuadroMACS[™] Separator were from Miltenyi Biotec, Bergisch Gladbach, Germany. CountBright[™] Absolute Counting Beads and fetal bovine serum (FBS) were purchased from Invitrogen, Carlsbad, CA. Anticoagulant Solution, buffered salt solution (BSS), Nucleic Acid Dye Solution (a 1,000-fold dilution of SYTO[®] 13 dye in DMSO), anti-human-CD59-PE (clone OV9A2), anti-human-CD55-PE (clone 143–30), anti-human-CD45-PE (clone HI30), and anti-human-CD61-PE (clone VI-PL2) were from Prototype Human MutaFlow[®] Kits (Litron Laboratories, Rochester, NY). Blood Freezing and Blood Thawing Solutions A and B were from MutaFlow[®] Blood Freezing and Thawing Kits (Litron Laboratories, Rochester, NY).

2.2.5 | Human blood *PIG-A* assay, sample processing and flow cytometric analysis—The method for preparing human blood samples for MUT RET scoring is similar to that described previously (Dertinger *et al.*, 2015). Two differences relative to the initial report are noteworthy. First, we scaled up reagents to label and analyze 200 µl blood (or 240 µl of frozen/thawed blood) per specimen as opposed to 100 µl. Second, since an effective blood freezing and thawing protocol was established (described below), a large portion of the *PIG-A* data reported herein were from samples that were frozen and later thawed for deferred flow cytometric analysis.

Freezing Solution (1 ml) was aliquoted into pre-labeled cryovials prior to freezing and maintained at room temperature. Upon receipt, human whole blood cells were gently resuspended by pipetting and 240 µl of blood was transferred into the Freezing Solution. Samples were incubated in Freezing Solution at room temperature for 5 min then transferred to a –75 to –85°C freezer. Samples were frozen for at least 48 hr before *PIG-A* analysis.

On the day of FCM analysis, up to 12 frozen blood samples were removed from the ultracold freezer and quickly thawed in a 37°C water bath. Once thawed (about 2 min), blood suspensions were moved to new pre-labeled 50 ml centrifuge tube. 0.9 ml Thawing Solution A was added to each tube and mixed by gentle pipetting up and down 6–8 times. Blood samples were incubated at room temperature for 5 min. After incubation, 4.5 ml Thawing Solution B was added to each tube and mixed by gentle pipetting followed by 5 min incubation at room temperature. Thawing Solution B was added again at 5 min intervals, first 5.4 ml and then 28.8 ml. After the final 5 min incubation, samples were centrifuged at 340g for 5 min, supernatants were aspirated, 100 µl BSS were added to each tube, and the cells were resuspended with gentle pipetting.

The entire volume of each thawed blood sample was layered onto 1.5 ml room temperature Lympholyte-H that was pre-aliquoted into wells of a deep-well 96-well plate (Axygen Scientific, 2 ml deep-well plate, cat. no. P-DW-20-C). In the case of never-frozen blood, 200 µl of blood was layered onto the Lympholyte-H. The plate was centrifuged at 800 × g for 20 minutes and supernatants were aspirated with a multi-channel aspirator with a fixed bridge (V&P Scientific, San Diego, CA). The platelet/leukocyte-depleted pellets were resuspended by gentle pipetting after 130 µl BSS were added to each well. The contents of each well were washed with an additional 1.5 ml cold BSS + 2%FBS that was pre-aliquoted into a new 96-well deep-well plate and the cells were collected via centrifugation for 10

min at 235g. 100 µl BSS were added to each well and the erythrocyte-enriched pellets were mixed by gentle pipetting, and 190 µl of each were transferred to new wells of the deep-well plate containing 200 µl working antibody solution (300 µl anti-CD59-PE stock, 12.5 µl anti-CD55-PE, 100 µl anti-CD61-PE, 50 µl anti-CD45-PE in 537.5 µl BSS + 2% FBS). After cells were incubated with antibodies for 30 min at 4°C, cells were resuspended with gentle pipetting using a multi-channel pipettor and then transferred to new wells of a deep-well plate with pre-aliquoted 1.5 ml of BSS + 2% FBS. Following centrifugation for 5 min at 340g, the supernatants were aspirated using a multi-channel bridge aspirator and 200 µl superparamagnetic anti-PE MicroBeads in BSS + 2% FBS (300 µl per ml) were added to each well. Cells and beads were mixed and incubated at 4°C for 30 min, 1.5 ml BSS + 2% FBS were added to each well after incubation and cells were mixed by gentle pipetting. The plate was centrifuged at 340g for 5 min, and supernatants were removed with a multi-channel fixed bridge aspirator, then 1 ml BSS + 2% FBS was added to each well and mixed by gentle pipetting. To prepare a pre-column sample, 10 µl of each sample were added to 990 µl BSS with Nucleic Acid Dye Solution and CountBright Absolute Counting Beads (30 µl/ml). The pre-column samples were incubated at room temperature and protected from light for 30 min, after which time they were stored on ice until flow cytometric analysis occurred as described below. The remainder of each sample was applied to a pre-wetted Miltenyi LS Column suspended in a QuadroMACS Separator. Once the column reservoir was empty, 5 ml BSS + 2% FBS were added to ensure mutant phenotype cells were fully eluted (and collected into a 15 ml polypropylene tube). The eluates were centrifuged for 5 min at 800g, supernatants were aspirated, the pellets were tapped loose, and 300 µl of the same preparation of BSS with Nucleic Acid Dye Solution and CountBright Beads used to prepare pre-column samples were added to each pellet. These post-column samples were incubated at room temperature and protected from light for 30 min. Samples were then placed on ice until flow cytometric analysis occurred as described previously on the same day (Dertinger *et al.*, 2015).

Samples were analyzed by a flow cytometer equipped with a 488-nm laser (FACSCalibur, BD, San Jose, CA). Nucleic Acid Dye, anti-CD59-PE, anti-CD55-PE, anti-CD45-PE, anti-CD61-PE, and Counting Beads fluorescence signals were detected in the FITC, PE, and PerCP-Cy5.5 channels. Calibration of the flow cytometer was accomplished by generating an Instrument Calibration Standard on each day data acquisition occurred. The resulting samples provided sufficient numbers of mutant-mimic cells (RBCs that were stained with Nucleic Acid Dye but not incubated with antibody solution), and were used for optimizing photomultiplier tube voltages and fluorescence compensation settings. The position of the mutant mimics also provided a rational approach for defining the vertical demarcation line used to distinguish mutant phenotype cells from wild-type cells.

After PMT voltages and electronic compensation setting were defined with the Instrument Calibration Standard, pre- and post-column samples were moved into standard flow cytometer tubes and analyzed within 2 hr. Data acquisition continued until a specified time: 1 min for every pre-column sample, and 3 min (i.e., until nearly the entire volume was depleted), for each post-column sample.

2.2.6 | Statistical analyses—The formulas used to calculate MUT RET frequencies based on pre- and post-immunomagnetic column data have been published (Dertinger *et al.*, 2012) and are described in MutaFlow kit manuals (www.litronlabs.com). The incidence of MN-RET is expressed as frequency percent, while the incidence of MUT RET is expressed as number per 10^6 cells. For statistical evaluations, MN-RET and MUT RET frequencies were $\log(10)$ transformed.

JMP software's Variability Chart platform was used to study sources of variability in MN-RET and MUT RET frequencies (JMP v12.0.1, SAS Institute Inc., Cary, NC). Specifically, the restricted maximum likelihood (REML) estimation of variance components was utilized, with the specification "nested" model type. REML is a statistical method that is a modification of maximum likelihood estimation, which allows the generalization of the "classic" regression and analysis of variance (ANOVA) statistical techniques to a wider series of experiments. For more information, the interested reader is directed to Corbeil and Searle, 1976. We utilized REML to evaluate the variability of MUT RET values attributable to subject, blood storage condition, and technical replicate. In other instances, REML was used to evaluate variability of MN-RET and MUT RET values attributable subject, blood collection time, and technical replicate.

Two-way ANOVA was used to investigate whether the factors age group, sex, and age group $\times$ sex interaction significantly affected MN-RET and MUT RET frequencies (JMP v12.0.1). Significance was evaluated at the 5% level. For these analyses, each subject was categorized into one of eight age groups: <1, 1–10, 11–20, 21–30, 31–40, 41–50, 51–60, and 61+ years of age. When two-way ANOVA was significant, a Tukey–Kramer test was used to identify the source of the variation ($\alpha = 0.05$).

JMP software's fit Y by X platform was used to plot MN-RET and MUT RET frequencies against subject age. Linear and polynomial curves were fitted, and the reported p -values represent a test of the hypothesis that the true slope coefficients are zero. Said another way, the test evaluates whether a particular fitted model explains the data significantly better than a mean fit line. Note that, in the case of MUT RET, these analyses were broken out by sex, since two-way ANOVA had indicated these values were affected by sex. A similar fit Y by X analysis was performed to consider the relationship between individuals' MN-RET and MUT RET frequencies.

Regression analysis was performed for every subjects' MUT RET and corresponding mutant erythrocyte (mutant RBC) frequencies. Additionally, Bland–Altman analysis was performed based on differences versus averages of MUT RET and mutant RBC values in order to describe bias and dispersion structures. Upper and lower limits of agreement were also calculated.

3 | RESULTS

3.1 | Assay optimization

3.1.1 | Reticulocyte enrichment for MN-RET analysis—Proof-of-concept work aimed at enriching RET for the micronucleus assay was accomplished with mouse blood.

Using gamma-irradiation to generate a range of MN-RET frequencies, we compared flow cytometry-based %MN-RET frequencies that were generated with and without immunomagnetic enrichment of CD71+ RET. Whereas standard processing of blood samples exhibited a mean %RET value of $1 \pm 0.55\%$, those that were enriched for CD71+ cells averaged $67 \pm 29\%$, a 68-fold increase. Even so, Figure 1 shows MN-RET frequencies for samples split between the standard flow cytometric analysis and those enriched for CD71+ RET exhibited very similar values. Indices of assay precision and accuracy were high, with r^2 and m values of 0.97 and 0.96, respectively. Bland–Altman analysis revealed little bias (0.09% MN-RET), with relatively narrow upper and lower levels of agreement.

Success with mouse blood encouraged us to develop an analogous RET-enrichment method for the human blood micronucleus assay. The most satisfactory results were obtained with the MACS[®] cell separation platform. Whereas the majority of human blood samples exhibited CD71+ RET frequencies in the range 0.1 to 0.3% prior to separation, post-immunomagnetic column samples averaged 26%—on the order of 100-times more concentrated. Figure 2 shows %MN-RET data from column-enriched samples for 14 different volunteers (5 males, 9 females). Each blood sample was split into 3–4 technical replicates. Since several volunteers provided multiple blood samples over a 5-week period, it was possible to evaluate inter- as well as intra-subject MN-RET variation. Based on REML analysis, the vast majority of variability is attributable to inter-subject differences (77.3%), with much less variability due to technical replicate (17.3%) or intra-subject variation (5.4%). (Note that for Figure 2 and others that display log transformed data, the visual impact of the between individual variability is reduced.)

3.1.2 | Blood storage for *PIG-A* analysis—The blood freezing and thawing method that has been proven effective for rodent samples was evaluated for its compatibility with human blood-based *PIG-A* analyses. Results for eight subjects are provided in Figure 3, and shows mutation frequency data under three blood storage conditions: (a) analyzed within 24 hr, (b) refrigerated for up to 5 days, and (c) frozen/thawed. REML analysis indicated that technical replicates and storage condition contributed low levels of variability to MUT RET frequencies—18.5 and 0%, respectively. The majority of the observed variability (81.5%) was attributable to inter-subject differences.

Figure 4 shows MUT RET data from the same 14 volunteers that were analyzed for %MN-RET (i.e., Figure 2). Each blood sample was divided into 3–4 technical replicates before storage and subsequent processing for MUT RET frequency determinations. Since several volunteers provided multiple blood samples over a 5-week period, it was possible to evaluate inter- as well as intra-subject MUT RET variation. Based on REML analysis, the vast majority of variability is attributable to inter-subject differences (90.9%). Again, considerably less variability was explained by technical replicate (9.1%) or intra-subject variation (0%).

3.2 | Investigating sources of inter-subject variation

3.2.1 | MN-RET: Age and sex effects—Using the optimized MN-RET assay, we investigated the effects of age and sex. Figure 5 shows MN-RET frequencies for 338

individuals as a function of age, with sexes indicated by different symbols. The values ranged from 0.01 to 0.79%, and the overall mean and standard deviation was $0.146 \pm 0.10\%$.

Visually, no age- or sex-effect is apparent. This qualitative impression is supported by several analyses. First, means and standard deviations for %MN-RET are very similar for males and females— $0.15 \pm 0.10\%$ and $0.14 \pm 0.10\%$, respectively. Second, when subjects are categorized by age (<1, 1–10, 11–20, 21–30 yr, etc.), two-way ANOVA results indicate that neither age group, sex, or an age group $\times$ sex interaction effect reaches statistical significance ($p = .14$, $.34$, and $.53$, respectively). Finally, when age is treated as a continuous variable, the mean fit line is found to describe the data as well as a best fit line ($p = .49$).

3.2.2 | MUT RET: Age and sex effects—Using the optimized *PIG-A* assay, we investigated the effects of age and sex on MUT RET frequency. Figure 6 shows MUT RET frequencies for 344 individuals as a function of age, with sexes indicated by different symbols. The values ranged from 0 to $1,109 \text{ MUT RET} \times 10^{-6}$, and the overall mean and standard deviation was $8.9 \pm 62 \times 10^{-6}$. When two extreme outliers are excluded, the values ranged from 0 to $40.7 \text{ MUT RET} \times 10^{-6}$, and the overall mean and standard deviation was $4.7 \pm 5.0 \times 10^{-6}$.

Visually, Figure 6 (left panel) suggests age and sex may influence MUT RET frequencies. These qualitative impressions are supported by several quantitative analyses. First, excluding two extreme (high) outliers, the mean MUT RET frequency is modestly elevated in males— 5.9 ± 6.2 compared to 3.5 ± 3.3 per million for females. Second, when subjects are categorized by age group (<1, 10–11, 11–20, 21–30 yr, etc.), two-way ANOVA results indicate that age group and sex reach statistical significance ($p < .001$ for both; whereas age group $\times$ sex interaction $p = .01$). Finally, when age is treated as a continuous variable, polynomial (cubic) fits describe the data significantly better than mean fit lines ($p < .001$ in the case of females and males; see Figure 6 middle and right panels).

Having identified age as a significant factor, we used the decade of age categorization to evaluate responsible group(s). A graphical representation of pair-wise test results is shown in Figures 7 and 8—females and males, respectively. The age group <1 yr was found to exhibit significantly lower MUT RET values than every other age group except for 1–10 (low N), and this was evident irrespective of sex. In the case of males, one other significant difference was evident between the age groups 21–30 and 51–60, with higher values observed with increased age. Note that while males 61+ actually exhibited the highest mean MUT RET value, the number of subjects in this group was low compared to each of the other groups.

3.3 | Relationship between biomarkers

Figure 9 shows each subjects' MN-RET value graphed against their corresponding MUT RET value. There is a striking lack of correlation between these two biomarkers. Indeed, the mean fit line explains the relationship between the two biomarkers as well as a best fit line ($p = .82$).

PIG-A assay results have focused on the youngest fraction of circulating erythrocytes, the RET cohort. This decision is based on the fact that in the case of human blood

circulation, mutant phenotype erythrocytes exhibit a shortened lifespan (Ware *et al.*, 1995). Data generated over the course of the current experiments supports this view. Figure 10 (left panel) shows each subject's MUT RET frequency graphed against the corresponding mutant RBC frequency. While the values are clearly correlated, the resulting slope (1.23) indicates that mutant RBC are considerably lower than MUT RET. This is reinforced by the Bland–Altman analysis (Figure 10, right panel). Beyond showing a negative bias, the dispersion structure indicates the bias is not uniform. Rather, as MUT RET values increase, the more mutant RBC values underestimate them.

4 | DISCUSSION

4.1 | Major findings

The results presented herein support the effectiveness and reliability of the new processing methods that include enrichment of CD71+ RET for subsequent MN-RET scoring, and storage of blood samples for deferred *PIG-A* assay analysis. These updated methods overcome technical issues that would have otherwise represented challenging obstacles to many, if not most, human biomonitoring applications.

Using the improved methodology, we found the variability of MN-RET and MUT RET measurements to be dominated by inter-subject variation, with only a minor contribution from intra-subject variability—at least over a 5-week period. Our analysis of hundreds of relatively healthy individuals over a wide range of ages suggest that neither age or sex significantly influence MN-RET frequency over the age range studied, 0–73 yr. On the other hand, MUT RET values were affected by age and sex, with the lowest frequencies being observed in the youngest subjects, and with males exhibiting moderately higher frequencies than females. It is important to acknowledge that, while these factors attained high statistical significance, some of the absolute differences were relatively modest. For instance, the overall mean MUT RET frequency for females and males was 3.5×10^{-6} versus 5.9×10^{-6} , respectively. The age effect appeared to be more substantial. For instance, in the case of the age groups <1 and 60+ yr, males exhibited mean MUT RET frequencies of $0.6 \pm 0.5 \times 10^{-6}$ versus $10.4 \pm 2.9 \times 10^{-6}$, respectively.

4.2 | Recommendations

The results presented herein have important implications for designing human biomonitoring studies using these genotoxicity biomarkers.

1. Given the effect that age and sex have on MUT RET frequencies, it will be important to balance experimental groups with these factors in mind. This design element would appear to be less critical in the case of the MN-RET endpoint.
2. We found that for both the MN-RET and MUT RET biomarkers, the majority of the variability is attributable to inter-subject differences, with little effect of blood collection time (i.e., intra-subject variability). Consequently, relatively large numbers of volunteers will be necessary to adequately power human biomonitoring studies when comparisons are restricted to differences among subjects. On the other hand, lower numbers of volunteers will be necessary for

experimental designs that are compatible with the collection of pre-intervention blood samples. In these cases, subject-specific baseline MN-RET and/or *PIG-A* mutation values will be available for consideration, an experimental design that will significantly reduce the number of study participants necessary to achieve a given level of statistical power.

3. There was a marked absence of correlation between individuals' MN-RET and MUT RET frequencies. For several reasons, this was an anticipated result. First, these biomarkers reflect distinct types of genomic damage—chromosomal damage versus gene mutation. Second, there are examples of genotoxicant-exposed rodents that have exhibited markedly dissimilar MN-RET and MUT RET responses (Dertinger *et al.*, 2012; Bhalli *et al.*, 2013; Guérard *et al.*, 2013; Elhajouji *et al.*, 2018). Third, MacGregor *et al.* (1997) reported a similar lack of correlation among several diverse human blood genotoxicity endpoints. With this information, investigators that are interested in adding a genotoxicity component to their human biomonitoring studies are advised to conduct multiple, complementary assays. The cost of performing multiple assays is incremental and modest compared to the costs associated with subject recruitment and other considerations, and the value added has the potential of being dramatic. This added value is readily accomplished by combining the MN-RET and *PIG-A* assays given their low blood volume requirements and the complementary nature of the genomic damage detected.
4. MUT RET and MUT RBC frequencies are correlated, and as expected, MUT RBC values consistently underestimate MUT RET frequencies. While systematic underestimation may not always be problematic, we are more concerned that Bland–Altman analysis shows a skewed dispersion structure whereby MUT RBC more greatly underestimate MUT RET as mutant cell frequencies increase. It is a fact that MUT RET analysis requires more resources relative to MUT RBC analysis—the former requires immunomagnetic separation, the latter does not. Even so, the MUT RET endpoint is demonstrably the preferred population of erythrocytes to study in the case of human blood biomonitoring studies.

4.3 | Future studies

Even in the case of MUT RET, where age and sex were found to be significant factors, the majority of the variability remains unexplained. Future work is needed to identify host and environmental factors that are responsible for inter-subject differences in MN-RET and MUT RET frequencies. That information would contribute to the design of more efficient human blood genotoxicity biomonitoring studies and would add fundamental knowledge to the field of cancer research, which considers genomic damage a key factor in the multistep process of carcinogenesis (Hanahan and Weinberg, 2000, 2011).

ACKNOWLEDGMENTS

This work was funded by a grant from the National Institute of Health/National Institute of Environmental Health Sciences (NIEHS; R44ES028163). The contents are solely the responsibility of the authors, and do not necessarily represent the official views of the NIEHS. The authors would like to thank the important contributions to this work

by Ying Tsai (mouse irradiation), Therese Smudzin and Cathy Zimmermann (IRB approval and recruitment of volunteers), and Merrie Lou Nagel (phlebotomy).

REFERENCES

- Altman DG and Bland JM (1983) Measurement in medicine: The analysis of method comparison studies. *Statistician*, 32, 307–317.
- Araten DJ, Nafa K, Pakdeesuwan K and Luzzatto L (1999) Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. *Proceedings of the National Academy of Sciences of the United States of America*, 96, 5209–5214. [PubMed: 10220445]
- Avlasevich SL, Torous DK, Bemis JC, Bhalli JA, Tebbe CC, Noteboom J, Thomas D, Roberts DJ, Barragato M, Schneider B, Prattico J, Richardson M, Gollapudi BB and Dertinger SD (2019) Suitability of long-term frozen rat blood samples for the interrogation of *Pig-a* gene mutation by flow cytometry. *Environmental and Molecular Mutagenesis*, 60(1), 47–55. [PubMed: 30264522]
- Bhalli JA, Ding W, Shaddock JG, Pearce MG, Dobrovolsky VN and Heflich RH (2013) Evaluating the weak in vivo micronucleus response of a genotoxic carcinogen, aristolochic acids. *Mutation Research*, 753(2), 82–92. [PubMed: 23500662]
- Cao Y, Yang L, Feng N, Shi O, Xi J, You X, Yin C, Yang H, Horibata K, Honma M, Qian B, Weng W and Luan Y (2016) A population study using the human erythrocyte *PIG-A* assay. *Environmental and Molecular Mutagenesis*, 57(8), 605–614. [PubMed: 27581231]
- Cao Y, Wang X, Liu W, Feng N, Xi J, You X, Chen R, Zhang X, Liu Z and Luan Y (2020a) The potential application of human *PIG-A* assay on azathioprine treated inflammatory bowel disease patients. *Environmental and Molecular Mutagenesis*, 61, 456–464. [PubMed: 31743483]
- Cao Y, Wang T, Xi J, Zhang G, Wang T, Liu W, You X, Zhang X, Xia Z and Luan Y (2020b) *PIG-A* gene mutation as a genotoxicity biomarker in human population studies: An investigation in lead-exposed workers. *Environmental and Molecular Mutagenesis*, in press. 10.1002/em.22373.
- Corbeil RR and Searle SR (1976) Restricted maximum likelihood (REML) estimation of variance components in the mixed model. *Technometrics*, 18, 31–38.
- Dertinger SD, Camphausen K, MacGregor JT, Bishop ME, Torous DK, Avlasevich S, Cairns S, Tometsko CR, Menard C, Muanza T, Chen Y, Miller RK, Cederbrant K, Sandelin K, Pontén I and Bolcsfoldi G (2004) Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood. *Environmental and Molecular Mutagenesis*, 44, 427–435. [PubMed: 15517570]
- Dertinger SD, Miller RK, Brewer K, Smudzin T, Torous DK, Roberts DJ, Avlasevich SL, Bryce SM, Sugunan S and Chen Y (2007) Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage. *Mutation Research*, 626, 111–119. [PubMed: 17059891]
- Dertinger SD, Bryce SM, Phonethepswath S and Avlasevich SL (2011) When pigs fly: Immunomagnetic separation facilitates rapid determination of *Pig-a* mutant frequency by flow cytometric analysis. *Mutation Research*, 721, 163–170. [PubMed: 21277384]
- Dertinger SD, Phonethepswath S, Avlasevich SL, Torous DK, Mereness J, Bryce SM, Bemis JC, Bell S, Weller P and MacGregor JT (2012) Efficient monitoring of *in vivo Pig-a* gene mutation and chromosomal damage: Summary of 7 published studies and results from 11 new reference compounds. *Toxicological Sciences*, 130, 328–348. [PubMed: 22923490]
- Dertinger SD, Avlasevich SL, Bemis JC, Chen Y and MacGregor JT (2015) Human erythrocyte *PIG-A* assay: An easily monitored index of gene mutation requiring low volume blood samples. *Environmental and Molecular Mutagenesis*, 56, 366–377. [PubMed: 25412990]
- Dobrovolsky VN, Elespuru RK, Bigger CA, Robison TW and Heflich RH (2011) Monitoring humans for somatic mutation in the endogenous *PIG-A* gene using red blood cells. *Environmental and Molecular Mutagenesis*, 52(9), 784–794. [PubMed: 21826740]
- Elhajouji A, Vaskova D, Downing R, Dertinger SD and Martus H (2018) Induction of *in vivo Pig-a* gene mutation but not micronuclei by 5-(2-chloroethyl)-2'-deoxyuridine, an antiviral pyrimidine nucleoside analogue. *Mutagenesis*, 33(5–6), 343–350. [PubMed: 30239881]

- Gollapudi BB, Lynch AM, Heflich RH, Dertinger SD, Dobrovolsky VN, Froetschl R, Horibata K, Kenyon MO, Kimoto T, Lovell DP, Stankowski LF Jr., White PA, Witt KL and Tanir JY (2015) The *in vivo Pig-a* mutation assay: A report of the international workshop of genotoxicity testing (IWGT) workgroup. *Mutation Research*, 783, 23–35. [PubMed: 25953398]
- Guérard M, Koenig J, Festag M, Dertinger SD, Singer T, Schmitt G and Zeller A (2013) Assessment of the genotoxic potential of azidothymidine in the comet, micronucleus, and *Pig-a* assay. *Toxicological Sciences*, 135(2), 309–316. [PubMed: 23811826]
- Grawé J, Biko J, Lorenz R, Reiners C, Stopper H, Vershenya S, Vukicevic V and Hempel K (2005) Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer. *Mutation Research*, 583, 12–25. [PubMed: 15866462]
- Haboubi HN, Lawrence RL, Rees B, Williams L, Manson JM, Al-Mossawi N, Bodger O, Griffiths P, Thornton C and Jenkins GJ (2019) Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma. *Scientific Reports*, 9(1), 5168. [PubMed: 30914682]
- Hanahan D and Weinberg RA (2000) The hallmarks of cancer. *Cell*, 100 (1), 57–70. [PubMed: 10647931]
- Hanahan D and Weinberg RA (2011) Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. [PubMed: 21376230]
- Hayashi M, MacGregor JT, Gatehouse DG, Adler I-D, Blakey DH, Dertinger SD, Krishna G, Morita T, Russo A and Sutou S (2000) In vivo rodent erythrocyte micronucleus assay: Aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring—A report from the international workshop on genotoxicity test procedures (IWGTP). *Environmental and Molecular Mutagenesis*, 35, 234–252. [PubMed: 10737958]
- Heddle J (1973) A rapid in vivo test for chromosome damage. *Mutation Research*, 18, 187–190. [PubMed: 4351282]
- Heflich RH, Johnson GE, Zeller A, Marchetti F, Douglas GR, Witt KL, Gollapudi BB and White PA (2020) Mutation as a toxicological endpoint for regulatory decision-making. *Environmental and Molecular Mutagenesis*, 61, 34–41. [PubMed: 31600846]
- Hoeijmakers JHJ (2009) DNA damage, aging, and cancer. *New England Journal of Medicine*, 361, 1475–1485.
- Horibata K, Ukai A, Ishikawa S, Sugano A and Honma M (2016) Monitoring genotoxicity in patients receiving chemotherapy for cancer: Application of the *PIG-A* assay. *Mutation Research*, 808, 20–26. [PubMed: 27637482]
- Khattab M, Walker DM, Albertini RJ, Nicklas JA, Lunblad LKA, Vacek PM and Walker VE (2017) Frequencies of micronucleated reticulocytes, a dosimeter of DNA double-strand breaks, in infants receiving computed tomography or cardiac catheterization. *Mutation Research*, 820, 8–18. [PubMed: 28676266]
- MacGregor J, Wehr C and Gould G (1980) Clastogen-induced micronuclei in peripheral blood erythrocytes: The basis of an improved micronucleus test. *Environmental Mutagenesis*, 2, 509–514. [PubMed: 6796407]
- MacGregor JT, Wehr CM, Hiatt RA, Peters B, Tucker JD, Langlois RG, Jacob RA, Jensen RH, Yager JW, Shigenaga MK, Frei B, Eynon BP and Ames BN (1997) Spontaneous genetic damage in man: Evaluation of interindividual variability, relationship among markers of damage, and influence of nutritional status. *Mutation Research*, 377, 125–135. [PubMed: 9219587]
- Offer T, Ho E, Traber MG, Bruno RS, Kuypers FA and Ames BN (2005) A simple assay for frequency of chromosome breaks and loss (micronuclei) by flow cytometry of human reticulocytes. *The FASEB Journal*, 19, 485–487. [PubMed: 15601670]
- Tometsko AM, Torous DK and Dertinger SD (1994) Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model. *Mutation Research*, 292(2), 129–135.
- Ware RE, Rosse WF and Hall SE (1995) Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. *Blood*, 86(4), 1586–1589. [PubMed: 7543308]
- Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E and Bishop JB (2007) Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine

in utero and postpartum to prevent mother-to-child transmission of HIV. *Environmental and Molecular Mutagenesis*, 48(3–4), 322–329. [PubMed: 17358032]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

FIGURE 1.

Micronucleated reticulocyte (MN-RET) frequencies are graphed for mouse blood samples that were each processed in two manners: immunomagnetically enriched versus not enriched for CD71-positive reticulocytes prior to flow cytometric analysis. The left panel shows linear regression and correlation analyses that provide metrics of accuracy ($m = 0.96$) and precision ($r^2 = 0.97$). The right panel shows the difference in MN-RET frequency for each sample in relation to the average value. Bias (solid black line) and upper and lower limits of agreement (dashed lines) were derived from Bland–Altman analysis

FIGURE 2. Log10 transformed micronucleated reticulocyte (MN-RET) frequencies are graphed for 14 volunteers, 5 of which provided blood over a 5-week period. Blood samples were processed as 3–4 technical replicates, and these individual MN-RET measurements are shown. Results from this nested design were evaluated by Restricted Maximum Likelihood analysis and demonstrated that inter-subject, intra-subject (collection time), and technical replicate factors contributed 77.3, 5.4, and 17.3% of the observed variation, respectively

FIGURE 3. Log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed for eight volunteers. Each blood sample was processed after being stored under 3 conditions: refrigerated 24 hr, refrigerated 5 days, and stored frozen until day of analysis. Blood samples were processed as 4 technical replicates, and these individual MUT RET measurements are graphed. Results from this nested design were evaluated by restricted maximum likelihood analysis and showed that inter-subject, storage condition, and technical replicate factors contributed 81.5, 0, and 18.5% of the observed variation, respectively

FIGURE 4. Log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed for 14 volunteers, 6 of which provided blood over a 5-week period. Blood samples were processed as 3–4 technical replicates, and these individual mutant measurements are shown. Results from this nested design were evaluated by Restricted Maximum Likelihood analysis and demonstrated that inter-subject, intra-subject (collection time), and technical replicate factors contributed 90.9, 0, and 9.1% of the observed variation, respectively

FIGURE 5.

Log10 transformed micronucleated reticulocyte (MN-RET) frequencies are graphed versus age (yr), with males as blue squares and females as red triangles. An ANOVA platform indicates that the best linear fit line (green solid line) does not describe the data any better than the mean fit line (orange), $p = .49$. The dashed lines correspond to the 95% prediction interval

FIGURE 6.

Log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed versus age (yr), with males as blue squares and females as red triangles. ANOVA indicates that cubic polynomial fits (orange solid lines) describe the data better than mean fit lines (green lines), $p < .001$ for both females (center panel) and males (right panel). The dashed lines correspond to 95% prediction intervals

FIGURE 7.

Female volunteers' log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed according to age group. Each group mean is indicated by a green line. Circles' diameters represent 95% confidence intervals. Tukey–Kramer test results indicate the age group <1 yr exhibited significantly lower MUT RET values compared to every other age group except for 1–10 yr (although it should be noted that group has low N)

FIGURE 8.

Male volunteers' log₁₀ transformed mutant reticulocyte (MUT RET) frequencies are graphed according to age group. Each group mean is indicated by a green line. Circles' diameters represent 95% confidence intervals. Tukey–Kramer test results indicate the age group <1 yr exhibited significantly lower MUT RET values compared to every other age group except for 1–10 yr (although it should be noted that group has low N). One additional significant difference was identified, between age groups 21–30 and 51–60. Note that while males 61+ actually exhibited the highest mean MUT RET value, the number of subjects in this group was low compared to each of the other groups

FIGURE 9.

Each subject's log10 transformed micronucleated reticulocyte (MN-RET) frequency is graphed against their corresponding mutant reticulocyte frequency, with males as blue squares and females as red triangles. ANOVA indicates that the best linear fit line (green) does not describe the data any better than the mean fit line (red), $p = .82$

FIGURE 10.

The left panel shows each subjects' mutant reticulocyte (MUT RET) frequency graphed against their corresponding mutant erythrocyte (MUT RBC) frequency. The values are correlated ($r^2 = 0.71$), but show a bias for lower MUT RBC values ($m = 1.23$). The right panel shows the difference in MUT RET and MUT RBC frequency for each sample in relation to the average value. Bias (solid black line) and upper and lower limits of agreement (dashed lines) were derived from Bland–Altman analysis. A linear regression line has been added to highlight the fact that there is a skewed dispersion structure to the data whereby MUT RBC more greatly underestimate MUT RET as mutant cell frequencies increase

Subject information

TABLE 1

Source	Total no. subjects (males/ females)	Age: Range (yr)	Age: Mean $\pm$ SD (yr)	Medical condition
Commercial supplier (Biological Specialty Company)	300 (150/150)	19–73	38.2 $\pm$ 12.1	Self-reported healthy adults
URMC, Department of radiation oncology	7 (2/5)	24–57	42.1 $\pm$ 11.2	Self-reported healthy adults
Texas Children's hospital, Department of pediatrics	26 (10/16)	0 (cord blood) – 1.2	0.2 $\pm$ 0.3	Healthy (cord bloods) or infants with congenital heart defect
URMC, Department of pediatrics	30 (11/19)	8–17	14.3 $\pm$ 3.0	Constipation or irritable bowel syndrome; otherwise healthy